An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials.
暂无分享,去创建一个
K. Mahaffey | M. Jardine | V. Perkovic | D. Matthews | B. Neal | H. Heerspink | B. Neuen | C. Arnott | Zien Zhou | Jingwei Li | Jie Yu